Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Prepublished online as a Blood First Edition Paper on March 13, 2003; DOI 10.1182/blood-2002-08-2508.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2002-08-2508v1
102/1/377    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thirukkumaran, C. M.
Right arrow Articles by Morris, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thirukkumaran, C. M.
Right arrow Articles by Morris, D. G.
Related Collections
Right arrow Hematopoiesis and Stem Cells
Right arrow Neoplasia
Right arrow Transplantation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 July 2003, Vol. 102, No. 1, pp. 377-387

TRANSPLANTATION

Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation

Chandini M. Thirukkumaran, Joanne M. Luider, Douglas A. Stewart, Tina Cheng, Sasha M. Lupichuk, Michael J. Nodwell, James A. Russell, Iwona A. Auer, and Donald G. Morris

From the Calgary Laboratory Services, Calgary, AB; Department of Medicine, Tom Baker Cancer Centre, Calgary, AB; and the Department of Medicine and Oncology, University of Calgary, AB, Canada.

Hematologic stem cell rescue after high-dose cytotoxic therapy is extensively used for the treatment of many hematopoietic and solid cancers. Gene marking studies suggest that occult tumor cells within the autograft may contribute to clinical relapse. To date purging of autografts contaminated with cancer cells has been unsuccessful. The selective oncolytic property of reovirus against myriad malignant histologies in in vitro, in vivo, and ex vivo systems has been previously demonstrated. In the present study we have shown that reovirus can successfully purge cancer cells within autografts. Human monocytic and myeloma cell lines as well as enriched ex vivo lymphoma, myeloma, and Waldenström macroglobulinemia patient tumor specimens were used in an experimental purging model. Viability of the cell lines or purified ex vivo tumor cells of diffuse large B-cell lymphoma, chronic lymphocytic leukemia, Waldenström macroglobulinemia, and small lymphocytic lymphoma was significantly reduced after reovirus treatment. Further, [35S]-methionine labeling and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of cellular proteins demonstrated reovirus protein synthesis and disruption of host cell protein synthesis as early as 24 hours. Admixtures of apheresis product with the abovementioned tumor cells and cell lines treated with reovirus showed complete purging of disease. In contrast, reovirus purging of enriched ex vivo multiple myeloma, Burkitt lymphoma, and follicular lymphoma was incomplete. The oncolytic action of reovirus did not affect CD34+ stem cells or their long-term colony-forming assays even after granulocyte colony-stimulating factor (G-CSF) stimulation. Our results indicate the ex vivo use of an unattenuated oncolytic virus as an attractive purging strategy for autologous stem cell transplantations. (Blood. 2003;102:377-387)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Virol.Home page
R. N. Douville, R.-C. Su, K. M. Coombs, F. E. R. Simons, and K. T. HayGlass
Reovirus Serotypes Elicit Distinctive Patterns of Recall Immunity in Humans
J. Virol., August 1, 2008; 82(15): 7515 - 7523.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
P. Rudd and G. Lemay
Correlation between interferon sensitivity of reovirus isolates and ability to discriminate between normal and Ras-transformed cells
J. Gen. Virol., May 1, 2005; 86(5): 1489 - 1497.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Craiu, Y. Saito, A. Limon, H. M. Eppich, D. P. Olson, N. Rodrigues, G. B. Adams, D. Dombkowski, P. Richardson, R. Schlossman, et al.
Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function
Blood, March 1, 2005; 105(5): 2235 - 2238.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. Q. Yang, X. Lun, C. A. Palmer, M. E. Wilcox, H. Muzik, Z. Q. Shi, R. Dyck, M. Coffey, B. Thompson, M. Hamilton, et al.
Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals: Racine and Nonhuman Primates
Clin. Cancer Res., December 15, 2004; 10(24): 8561 - 8576.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. L. Norman, K. Hirasawa, A.-D. Yang, M. A. Shields, and P. W. K. Lee
Reovirus oncolysis: The Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection
PNAS, July 27, 2004; 101(30): 11099 - 11104.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020